Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Trancription profiling of breast tumor biopsies to identify markers of Taxane Sensitivity in Breast Cancer


ABSTRACT: The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant paclitaxel/radiation treatment, protein and gene expression profiling were done on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with three cycles of paclitaxel followed by concurrent paclitaxel/radiation. Tumor tissue from pretreatment biopsies was obtained from 19 of the 38 patients enrolled in the study. Protein and gene expression profiling were done on serial sections of the biopsies from patients that achieved a pathologic complete response (pCR) and compared to those with residual disease, non-pCR (NR). Proteomic and validation immunohistochemical analyses revealed that α-defensins (DEFA) were overexpressed in tumors from patients with a pCR. Gene expression analysis revealed that MAP2, a microtubule-associated protein, had significantly higher levels of expression in patients achieving a pCR. Elevation of MAP2 in breast cancer cell lines led to increased paclitaxel sensitivity. Furthermore, expression of genes that are associated with the basal-like, triple-negative phenotype were enriched in tumors from patients with a pCR. Analysis of a larger panel of tumors from patients receiving presurgical taxane-based treatment showed that DEFA and MAP2 expression as well as histologic features of inflammation were all statistically associated with response to therapy at the time of surgery. We show the utility of molecular profiling of pretreatment biopsies to discover markers of response. Our results suggest the potential use of immune signaling molecules such as DEFA as well as MAP2, a microtubule-associated protein, as tumor markers that associate with response to neoadjuvant taxane–based therapy. Tumor tissues from pretreatment needle biopsies from patients enrolled on a paclitaxel/radiation clinical trial were laser capture microdissected for RNA extraction and hybridization to Affymetrix microarrays. We analyzed one array (sample A) from duplicate samples from each patient. 14 subject, 2 replicates each.

ORGANISM(S): Homo sapiens

SUBMITTER: Jennifer Pietenpol 

PROVIDER: E-GEOD-22513 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.

Bauer Joshua A JA   Chakravarthy A Bapsi AB   Rosenbluth Jennifer M JM   Mi Deming D   Seeley Erin H EH   De Matos Granja-Ingram Nara N   Olivares Maria G MG   Kelley Mark C MC   Mayer Ingrid A IA   Meszoely Ingrid M IM   Means-Powell Julie A JA   Johnson Kimberly N KN   Tsai Chiaojung Jillian CJ   Ayers Gregory D GD   Sanders Melinda E ME   Schneider Robert J RJ   Formenti Silvia C SC   Caprioli Richard M RM   Pietenpol Jennifer A JA  

Clinical cancer research : an official journal of the American Association for Cancer Research 20100112 2


<h4>Purpose</h4>To identify molecular markers of pathologic response to neoadjuvant paclitaxel/radiation treatment, protein and gene expression profiling were done on pretreatment biopsies.<h4>Experimental design</h4>Patients with high-risk, operable breast cancer were treated with three cycles of paclitaxel followed by concurrent paclitaxel/radiation. Tumor tissue from pretreatment biopsies was obtained from 19 of the 38 patients enrolled in the study. Protein and gene expression profiling were  ...[more]

Similar Datasets

2010-06-23 | GSE22513 | GEO
2011-04-22 | GSE28796 | GEO
2011-04-22 | E-GEOD-28796 | biostudies-arrayexpress
2022-09-01 | GSE207248 | GEO
2022-11-08 | PXD034355 | Pride
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
2019-06-19 | PXD010112 | Pride
2021-01-08 | GSE164458 | GEO
2013-01-01 | GSE41998 | GEO
2021-09-30 | GSE179730 | GEO